Auliya Abdurrohim Suwantika

Dr. Auliya Abdurrohim Suwantika

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
FZFelix Zulhendri
Felix Zulhendri
RLRonny Lesmana
Ronny Lesmana
STSteven Tandean
Steven Tandean
ACAndreas Christoper
Andreas Christoper
KAVITA CHANDRASEKARANKAVITA CHANDRASEKARAN
KAVITA CHANDRASEKARAN
Nasrul WathoniNasrul Wathoni
Nasrul Wathoni
In recent years, research has demonstrated the efficacy propolis as a potential raw material for pharmaceuticals and nutraceuticals. There is limited report detailing the mechanisms of action of propolis and its bioactive compounds in relation to their anti-inflammatory properties. Thus, the aim of the present review is to examine the latest experimental evidence (2017–2022) regarding the anti-inflammatory properties of propolis. A systematic scoping review methodology was implemented. After applying the exclusion criteria, a total of 166 research publications were identified and retrieved from Scopus, Web of Science, and Pubmed. Several key themes related to the anti-inflammatory properties of propolis were subsequently identified, namely in relation to cancers, oral health, metabolic syndrome, organ toxicity and inflammation, immune system, wound healing, and pathogenic infections. Based on the latest experimental evidence, propolis is demonstrated to possess various mechanisms of action in modulating inflammation towards the regulatory balance and anti-inflammatory environment. In general, we summarize that propolis acts as an anti-inflammatory substance by inhibiting and downregulating TLR4, MyD88, IRAK4, TRIF, NLRP inflammasomes, NF-κB, and their associated pro-inflammatory cytokines such as IL-1β, IL-6, IFN-γ, and TNF-α. Propolis also reduces the migration of immune cells such as macrophages and neutrophils, possibly by downregulating the chemokines CXCL9 and CXCL10.

1 January 2022 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
GCGabriella J Caren
Gabriella J Caren
DIDeni Iskandar
Deni Iskandar
DPDian Ae Pitaloka
Dian Ae Pitaloka
RARizky Abdulah
Rizky Abdulah
ASAuliya Abdurrohim Suwantika
Auliya Abdurrohim Suwantika
The current coronavirus disease 2019 (COVID-19) situation might deteriorate the efforts to eliminate tuberculosis (TB) in Indonesia. This study aimed to review the COVID-19 pandemic disruption on the management of TB treatment in Indonesia. We identified several disruptions due to the pandemic on TB control management. Firstly, there is a potential decrease in the funding for TB treatment. Financial disruptions caused by the COVID-19 pandemic have led to further setbacks. In many countries, including Indonesia, financial and other resources have been reallocated from TB to the COVID-19 response. Secondly, it has been highlighted that all TB services, including case detection and rapid diagnostic, have been disrupted by the pandemic. Thirdly, the pandemic would be associated with the lower quality of care and treatment for TB in Indonesia. It might decrease the enthusiasm of patients with TB, multi-drug resistant (MDR)-TB, and TB-human immunodeficiency virus (HIV) to visit TB hospitals because of social distancing measures by the government. Finally, the COVID-19 pandemic also has impacted critical activities of monitoring, evaluation, and surveillance. There are several lessons from other countries about managing TB treatment during the pandemic, such as combining screening for COVID-19 and TB by applying x-ray technology and artificial intelligence-based software. In addition, the use of telemedicine or telehealth in TB treatment is also beneficial to deliver medication, assess patients’ progress, and inform prevention strategies. To reach the target with the end TB strategy, the government of Indonesia can adopt the World Health Organization’s (WHO’s) comprehensive strategies, such as integrated, patient-centered TB care and prevention strategies; bold policies and supportive systems; and intensified research and innovations.

6 February 2024 in Globalization and Health
Verified
Journal Article
Open access
PDF file
RSRano K. Sinuraya
Rano K. Sinuraya
RNRina F. Nuwarda
Rina F. Nuwarda
MPMaarten J. Postma
Maarten J. Postma
ASAuliya Abdurrohim Suwantika
Auliya Abdurrohim Suwantika
Introduction: Indonesia has made progress in increasing vaccine coverage, but equitable access remains challenging, especially in remote areas. Despite including vaccines in the National Immunization Program (NIP), coverage has not met WHO and UNICEF targets, with childhood immunization decreasing during the COVID-19 pandemic. COVID-19 vaccination has also experienced hesitancy, slowing efforts to end the pandemic. Scope: This article addresses the issue of vaccine hesitancy and its impact on vaccination initiatives amidst the COVID-19 pandemic. This article utilizes the vaccine hesitancy framework to analyze previous outbreaks of vaccine-preventable diseases and their underlying causes, ultimately providing recommendations for addressing the current situation. The analysis considers the differences between the pre-pandemic circumstances and the present and considers the implementation of basic and advanced strategies. Key findings and conclusion: Vaccine hesitancy is a significant challenge in the COVID-19 pandemic, and public health campaigns and community engagement efforts are needed to promote vaccine acceptance and uptake. Efforts to address vaccine hesitancy promote trust in healthcare systems and increase the likelihood of individuals seeking preventive health services. Vaccine hesitancy requires a comprehensive, culturally sensitive approach that considers local contexts and realities. Strategies should be tailored to specific cultural and societal contexts and monitored and evaluated.

1 February 2023 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
IDInge Dhamanti
Inge Dhamanti
ASAuliya Abdurrohim Suwantika
Auliya Abdurrohim Suwantika
AAAmirah Adlia
Amirah Adlia
LYLaura Navika Yamani
Laura Navika Yamani
FYFitri Yakub
Fitri Yakub
The COVID-19 pandemic had a severe global impact. A range of campaigns and activities, including vaccines, are being implemented to counteract this pandemic. Using observational data, the goal of this scoping review is to identify adverse events connected with COVID-19 vaccinations. We conduct a scoping study and searched three databases from the start of the COVID-19 pandemic in 2020 through June 2022. Based on our criteria and searched keywords, the review included eleven papers in total, with the majority of the studies being conducted in developed countries. The study populations varied and included general community populations, healthcare professionals, military forces, and patients with systemic lupus and cancer. This study includes vaccines from Pfizer-BioNTech, Oxford-AstraZeneca, Sinopharm, and Moderna. The COVID-19 vaccine-related adverse events were classified into three types: local side effects, systemic side effects, and other side effects such as allergies. The adverse reactions to COVID-19 vaccines are mild to moderate in severity, with no significant influence or interference in individual daily activities and no unique patterns in cause of death among vaccine-related deaths. According to the findings of these investigations, the COVID-19 vaccine is safe to administer and induces protection. It is vital to convey accurate information to the public about vaccination side effects, potential adverse responses, and the safety level of the vaccines supplied. Multiple strategies must be implemented at the individual, organizational, and population levels to eliminate vaccine hesitance. Future studies could investigate the vaccine’s effect on people of various ages and medical conditions.

1 January 2022 in Patient Preference and Adherence
Verified
Journal Article
Open access
RSRano Sinuraya
Rano Sinuraya
AKArif Sw Kusuma
Arif Sw Kusuma
ZPZinzi E Pardoel
Zinzi E Pardoel
MPMaarten J Postma
Maarten J Postma
ASAuliya Abdurrohim Suwantika
Auliya Abdurrohim Suwantika
Vaccination is known to have an enormous impact on improving child health. In Indonesia, the government has included several vaccines in the national immunization program. This study aimed to investigate parents’ knowledge, attitude, and practice on childhood immunization during the COVID-19 pandemic in Indonesia. A valid and reliable questionnaire was delivered to approximately 276 parents in Jakarta and Bandung, representing the epicenter of the pandemic. This study was conducted from June 2020 to February 2021. The correlations between parents’ knowledge, attitudes, and practice with the characteristics of the respondents were investigated. In addition, multiple regression analysis was performed to identify the variables associated with good vaccination practice. The results showed that the mean scores of parents’ knowledge, attitude, and practice on childhood vaccinations were 7.22 (± 1.30) out of 9 points, 3.93 (± 0.31) out of 4 points, and 3.59 (± 0.97) out of 5 points, respectively. Respondents graduated from university were more knowledgeable than those graduated from senior high school (p-value <0.05). Employed participants had better scores in knowledge and practice, compared to unemployed participants (p-value <0.05). In conclusion, this study found positive correlations between participants’ knowledge and attitude, knowledge and practice, and attitude and practice on childhood vaccination during the COVID-19 pandemic in Indonesia.

2 August 2020 in Expert Review of Vaccines
Verified
Journal Article
Closed access
ASAuliya Abdurrohim Suwantika
Auliya Abdurrohim Suwantika
CBCornelis Boersma
Cornelis Boersma
MPMaarten J. Postma
Maarten J. Postma
(2020). The potential impact of COVID-19 pandemic on the immunization performance in Indonesia. Expert Review of Vaccines. Ahead of Print.